The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Characterizing Region-specific Lipid Profiles in Parkinson’s Disease and Gaucher Disease
Study Rationale: Mutations in the GBA1 gene, which encodes glucocerebrocidase (GCase), is the most prevalent risk factor for Parkinson’s disease (PD). The resulting deficit in GCase activity leads to...
-
Therapeutic Pipeline Program, 2023Developing A Small-Molecule Activator of AMPK for the Treatment of Parkinson’s Disease
Study Rationale: Overwhelming evidence indicates that mitochondrial dysfunction contributes to the development of Parkinson’s disease (PD). We discovered that drugs that activate the enzyme AMPK...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Implementation and Validation of Lysosome-specific Tests of GCase Activity in Cell Lines and Human Peripheral Blood
Study Rationale: Glucocerebrosidase (GCase) is an enzyme that is linked to Parkinson’s disease (PD) and is a high value target for disease-modifying treatments. Developing robust methods for...
-
Translational Pipeline Program, 2023Identifying Small Molecule Inducers of Autophagy and Lysosomes
Study Rationale: Neurons keep themselves healthy and free of damaged cellular materials using an internal garbage collection system called autophagy and internal recycling centers called lysosomes...
-
Research Grant, 2023Measuring Quality of Life in People with Parkinson’s Disease: State of the Art and Areas for Development
Study Rationale: Scales to measure quality of life are important tools for research. However, it is unclear whether currently available scales for measuring quality of life take into account the...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Validation of KLK6 as a New Therapeutic Target for Parkinson’s Disease
Study Rationale: Alpha-synuclein is the main protein that aggregates and forms Lewy bodies, the hallmark histological characteristics of Parkinson disease (PD). Multiple experimental studies suggest...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.